Navigation Links
Results triple researchers' projections with use of adult stem cells for heart failure
Date:11/14/2011

ORLANDO, Fla. Patients suffering from heart failure due to a previous myocardial infarction showed an average of 12 percent improvement one year following an investigative treatment that involved infusing them with their own stem cells. The results triple the 4 percent improvement average the researchers projected for the Phase I trial.

Results of the trial are published today (Nov. 14) in The Lancet and concurrently presented at the American Heart Association Scientific Sessions in Orlando, Fla. They are the first report of administering subjects' own cardiac stem cells in humans; previous studies have used stem cells harvested from bone marrow.

The research team, led by Dr. Roberto Bolli of the University of Louisville and Dr. Piero Anversa at Brigham and Women's Hospital/Harvard Medical School in Boston, conducted the trial, called "SCIPIO" an acronym for "Cardiac Stem Cells in Patients with Ischemic CardiOmyopathy."

The 16 SCIPIO patients were diagnosed with heart failure following a myocardial infarction and had a left ventricular ejection fraction (LVEF) of 40 percent or lower. LVEF is a standard measure of the heart's pumping capability; it measures how much blood is ejected from the left ventricle during a heartbeat. The normal LVEF is 50 percent or higher.

The investigators harvested cardiac stem cells, referred to as "c-kit positive" cells because they express the c-kit protein on their surface, from the patients during coronary artery bypass surgery conducted at Jewish Hospital in Louisville. The stem cells were purified in Anversa's lab in Boston and allowed to grow. Once an adequate number of stem cells were produced about one million Bolli's team in Louisville reintroduced them into the region of the patient's heart that had been scarred by the infarction.

In designing the trial, Bolli and Anversa examined data from previous studies of bone marrow-derived stem cells and projected an average improvement in LVEF of 4-5 percent for all patients. They witnessed an 8.5 percent improvement just four months following the reintroduction of stem cells and 12 percent after one year.

The researchers also conducted MRI studies on the patients' hearts and saw that the size of the scarred regions had decreased a result that seemingly begins to disprove the long-held belief that once scarring occurs, the heart tissue is forever dead.

Bolli who is lead author of The Lancet article and presenter of the data at the Scientific Sessions says that the adult stem cell protocol could become one of the greatest advancements in cardiac treatment in a generation.

"The results are striking," Bolli said. "While we do not yet know why the improvement occurs, we have no doubt now that ejection fraction increased and scarring decreased. If these results hold up in future studies, I believe this could be the biggest revolution in cardiovascular medicine in my lifetime."

His colleague Anversa has been studying cardiac stem cells' potential to regenerate myocardial cells damaged from heart failure since the 1990s. "Seeing these cells given successfully to very sick patients is the most rewarding experience that a physician-scientist can have in his or her lifetime," said Anversa, noting that the work was a major team effort that involved several senior members in both his and Bolli's laboratories.

The SCIPIO trial was funded by a grant from the National Heart, Lung and Blood Institute. The researchers reiterated that these findings are preliminary and larger-scale studies must be undertaken before the therapy can be widely used.

Bolli already is looking forward to a larger study, he said. "We plan to apply for funding to conduct a Phase II multi-center trial," he said.


'/>"/>

Contact: Jill Scoggins
jill.scoggins@louisville.edu
502-475-2428
University of Louisville
Source:Eurekalert  

Related biology news :

1. Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT
2. Reprogramming stem cells to a more basic form results in more effective transplant, study shows
3. Progeria: Promising results from new gene therapy on animals
4. Aware, Inc. Reports Third Quarter 2011 Financial Results
5. Vanderbilt ethicist to study return of results issue involving children in genomics studies
6. CONRAD presents results of pivotal contraceptive study at Reproductive Health 2011
7. Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome
8. Aware, Inc. Reports Second Quarter 2011 Financial Results
9. Montana State University team surprised by results of lung, mold study
10. National asthma genetics consortium releases first results
11. Aware, Inc. Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Results triple researchers' projections with use of adult stem cells for heart failure
(Date:1/30/2017)... 30, 2017   Invitae Corporation (NYSE: ... information companies, today announced that it will report its ... 2017 guidance on Monday, February 13, 2017, and Invitae,s ... at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... briefly review financial results, guidance, and recent developments and ...
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... San Francisco, CA (PRWEB) , ... February 21, ... ... is pleased to announce that Dr. Trevor Heritage has joined its executive team ... a revolutionary system designed to provide insights to help improve the diagnosis and ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... GMP cell therapy manufacturing facility at its headquarters laboratory in Poway, California. ... utilizing the experience of both in-house personnel and consultants, VetStem constructed and validated ...
(Date:2/21/2017)... a returning partner of the Amgen Tour of California , ... of the men,s and women,s events for the next five editions ... of California will mark the start of ... cycling teams in the world racing from Northern to ... from Heart Disease TM Women,s Race empowered with SRAM ...
(Date:2/21/2017)... 2017   Invitae Corporation (NYSE: NVTA), one ... that members of the company,s management team will present ... Conference on Monday, March 6, 2017 at approximately 4:00 ... Boston, Massachusetts . The live, ... visiting the investors section of the company,s website at ...
Breaking Biology Technology: